Johnson & Johnson is acquiring Halda Therapeutics for $3.05 billion.

Johnson & Johnson (JNJ) has made a significant agreement with Halda Therapeutics to increase its investments in the healthcare sector. The company has agreed to a total cash payment of $3.05 billion for Halda Therapeutics.

This acquisition stands out as part of Johnson & Johnson's strategy to expand its drug development portfolio. The details of the agreement highlight the combination of Halda Therapeutics’ innovative treatment methods with its high growth potential in the healthcare sector.